Figure 1

Immunohistochemical analysis and expression of pazopanib targets in TGT44. A) Histological and immunohistochemical characterization of TGT44, CDDP-treated TGT44 (with three injections of 4 mg/kg CDDP) and the original tumor biopsy: (a-f) Hematoxylin-eosin staining (a-c: 150x, bar 100 μm; d-f: 400x, bar 100 μm); (g-i) CAM5.2 immunostaining; (j-l) EMA immunostaining; (m-o) AFP immunostaining. 400x, bar 100 μm. B) c-KIT expression in TGT44 and original tumor biopsy was characterized by immunohistochemical analysis. 400x, bar 100 μm. C) Expression of PDGFRα and PDGFRβ receptors, and tubulin as a loading control, was analyzed by western blot of two TGT44 independent tumors. D) mRNA levels of human PDGFRα and PDGFRβ were analyzed by quantitative real-time PCR in TGT44, TGT1, TGT38 orthotopic tumor models, and in GCT27 and 1411H testicular cell lines. Results are expressed as 2^(−ΔCt)·10⁴ (with SD).